InsiderTrades.com logo
Trump’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media   |   Ad
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
YES, I WANT THE #1 CRYPTO NOW
Jonathan D. Root net worth and biography
  • Phone
  • Email
  • Website

Jonathan Root Biography and Net Worth

Director of eFFECTOR Therapeutics
Jonathan Root spent nine years in clinical practice before joining USVP in 1995 as an Ewing Marion Kauffman Fellow in venture capital. He became a general partner in 1997. Before USVP, Dr. Root was on the faculty and clinical staff at The New York Hospital-Cornell Medical Center in New York City. There he was an assistant professor of neurology and director of the neurology-neurosurgery special care unit. He is board certified in neurology. Dr. Root is currently on the boards of USVP portfolio companies of Cleave Biosciences, eFFECTOR Therapeutics, Inari Medical, Omada Health, Ribon and Route 92 Medical. Dr. Root is a former board member for the National Venture Capital Association (NVCA). He holds an A.B. in economics from Dartmouth College, an M.D. from the University of Florida College of Medicine and an M.B.A. from Columbia University.

What is Jonathan D. Root's net worth?

The estimated net worth of Jonathan D. Root is at least $3.13 as of March 30th, 2021. Dr. Root owns 15,625 shares of eFFECTOR Therapeutics stock worth more than $3 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Root may own. Learn More about Jonathan D. Root's net worth.

How do I contact Jonathan D. Root?

The corporate mailing address for Dr. Root and other eFFECTOR Therapeutics executives is 200 CLARENDON STREET 51ST FLOOR, BOSTON MA, 02116. eFFECTOR Therapeutics can also be reached via phone at 858-925-8215 and via email at [email protected]. Learn More on Jonathan D. Root's contact information.

Has Jonathan D. Root been buying or selling shares of eFFECTOR Therapeutics?

Jonathan D. Root has not been actively trading shares of eFFECTOR Therapeutics in the last ninety days. Most recently, Jonathan D. Root sold 324 shares of the business's stock in a transaction on Thursday, December 2nd. The shares were sold at an average price of $142.00, for a transaction totalling $46,008.00. Learn More on Jonathan D. Root's trading history.

Who are eFFECTOR Therapeutics' active insiders?

eFFECTOR Therapeutics' insider roster includes Christopher Ehrlich (Director), and Jonathan Root (Director). Learn More on eFFECTOR Therapeutics' active insiders.

Are insiders buying or selling shares of eFFECTOR Therapeutics?

During the last twelve months, insiders at the sold shares 1 times. They sold a total of 24,366 shares worth more than $371,581.50. The most recent insider tranaction occured on November, 27th when Major Shareholder Sr One Capital Management, Llc sold 24,366 shares worth more than $371,581.50. Insiders at eFFECTOR Therapeutics own 4.7% of the company. Learn More about insider trades at eFFECTOR Therapeutics.

Information on this page was last updated on 11/27/2023.

Jonathan D. Root Insider Trading History at eFFECTOR Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2021Sell324$142.00$46,008.00View SEC Filing Icon  
11/30/2021Sell1,096$163.25$178,922.00View SEC Filing Icon  
11/26/2021Sell201$175.25$35,225.25View SEC Filing Icon  
11/24/2021Sell1,460$184.00$268,640.00View SEC Filing Icon  
11/22/2021Sell1,047$196.50$205,735.50View SEC Filing Icon  
11/19/2021Sell289$203.00$58,667.00View SEC Filing Icon  
11/17/2021Sell409$228.25$93,354.25View SEC Filing Icon  
11/15/2021Sell202$245.25$49,540.50View SEC Filing Icon  
11/11/2021Sell480$259.25$124,440.00View SEC Filing Icon  
11/9/2021Sell1,151$275.00$316,525.00View SEC Filing Icon  
See Full Table

Jonathan D. Root Buying and Selling Activity at eFFECTOR Therapeutics

This chart shows Jonathan D Root's buying and selling at eFFECTOR Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

eFFECTOR Therapeutics Company Overview

eFFECTOR Therapeutics logo
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: $0.02
Low: $0.00
High: $0.05

2 Week Range

Now: $0.00
Low: $0.00
High: $17.90

Volume

8,317 shs

Average Volume

16,095 shs

Market Capitalization

$940.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81
Trump’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media   |   Ad
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
YES, I WANT THE #1 CRYPTO NOW